NCIC CTG LUNG CANCER SITE ANNUAL MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, October 18, 2003 - 8:30 a.m. - 4:15 p.m.
Room: Churchill Ballroom A
Chair: Dr. Frances Shepherd

8:30 a.m.  Results of External Site Review for US NCI  
Dr. F. Shepherd

8:45 a.m.  Review of Lung site Retreat  
Dr. F. Shepherd

NON-SMALL CELL LUNG CANCER

9:00 a.m.  Surgical Adjuvant and Neoadjuvant Trials

BR.10 - Adjuvant navelbine/cisplatin in Stage I-II NSCLC  
Dr. T. Winton

BR.16 - Randomized placebo controlled trial of adjuvant Selenium  
in completely resected stage I NSCLC (ECOG)  
Dr. F. Shepherd

BR.19 - Randomized trial of adjuvant Iressa versus placebo  
after complete resection of Stage IB, II IIIA NSCLC  
Dr. G. Goss

BR.22 - Induction chemotherapy versus immediate surgery in  
Early stage NSCLC (SWOG)  
Dr. Peter Ellis

BR. 23 - Phase II trial of etoposide/cisplatin/XRT followed by  
Surgery and consolidation Taxotere for Pancoast tumours  
Dr. S. Laurie

ES. 2 - Palliative radiation for esophageal cancer  
Dr. R. Wong

10:00 a.m.  COFFEE BREAK

10:45 a.m.  ADVANCED NSCLC

BR.15 - Chemotherapy and radiotherapy +/- Iressa In Stage IIIB  
NSCLC (SWOG)  
Dr. Y. Ung

BR.18 - Taxol/carboplatin +/- BMS275291 in advanced NSCLC  
Dr. N. Leighl

BR.21 - Randomized trial of Tarceva versus placebo as 2nd or 3rd  
line treatment of advanced NSCLC  
Dr. F. Shepherd

BR.17 - Randomized comparison of Tomudex/cisplatin versus  
Cisplatin alone in Malignant Mesothelioma (EORTC)  
Dr. M. Vincent

continued . . .
12:00 - 1:00 Lunch

1:00 p.m. Small Cell Lung Cancer

BR.20 - Randomized Phase II trial of ZD6474 versus placebo in responding patients with SCLC

Dr. A. Arnold

New Studies Under Consideration and Non-NCIC Trials

PCI in NSCLC (RTOG) Dr. A. Sun
PCI in SCLC (RTOG) Dr. A. Sun
Possible trial of Taxotere +/- SCH66336 in second line NSCLC Dr. F. Shepherd

2:15 Coffee Break

Phase I trial of chemotherapy/XRT and ZD6126 in NSCLC Dr. A Brade
Possible randomized Phase II trial of Iressa versus standard Dr. R. Feld
Combination chemotherapy as first-line treatment for N-SCLC

CTSU trial E4599 - Taxol/carbo +/- Avastin in stage IIIB and IV NSCLC Dr. F. Shepherd